Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Open Label, Phase Ib/II Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Patients eligible to participate in this trial will initially receive 6 cycles of obinutuzumab, venetoclax and lenaliomide. Each cycle consists of 28 days. After the initial treatment, a PET-CT scan will be conducted and depending upon the PET-CT scan results maintenance treatment may be received for up to 2 years. Followup will continue for 3 years after the last enrolled patient has received the induction treatment.